Company: LGN
Filing Date: 2025-07-15
Form Type: DRS/A
Source: 0000950123-25-006399
Chunk: 304

Company: Legence Corp.
Filing Date: 2025-07-15
Form: DRS/A
Chunk 304
---
 amended the swap agreements to transition its benchmark interest from LIBOR to SOFR. Failure of the interest rate swap counterparties to make payments may result in the loss of any potential benefit to the Company under the interest rate swap agreements. The Company mitigates risk of non-performanceby counterparties by dealing with highly rated counterparties. The Company does not use financial instruments for trading or speculative purposes. Additional information regarding the accounting policies and relevant fair value information for the Company’s interest rate swaps can be found in “ Note 2—Summary of Significant Accounting Policies” and “ Note 10—Fair Value Measurements.” The fair value of derivative instruments is presented in the Consolidated Balance Sheets, as follows (in thousands):

| Derivatives designated as hedging instruments |     | Balance sheet location                    |     | December 31, 
 2024         |       |     | 2023 |        |
|:----------------------------------------------|:----|:------------------------------------------|:----|:-------------|------:|:----|:-----|-------:|
| Interest rate swap asset (short-term)         |     | Prepaid expenses and other current assets |     | $            | 5,861 |     | $    | 22,052 |
| Interest rate swap asset (long-term)          |     | Other assets                              |     | $            | 3,387 |     | $    |  1,296 |
| Interest rate swap liability (long-term)      |     | Other long-term liabilities               |     | $            |   137 |     | $    |  1,182 |

F-48

Confidential Treatment Requested by Legence Corp. Pursuant to 17 C.F.R. Section 200.83 Legence Holdings LLC and Subsidiaries Notes to Consolidated Financial Statements The following table presents the gross changes in AOCI from the Company’s cash flow hedges (in thousands). There was no tax impact for the years presented.

|                                                                                |     |   |    2024 |   |     |   |    2023 |   |     |   |   2022 |   |
|:-------------------------------------------------------------------------------|:----|:--|--------:|:--|:----|:--|--------:|:--|:----|:--|-------:|:--|
| Accumulated gain in AOCI at the beginning of year                              |     | $ |  22,166 |   |     | $ |